Adjuvant radiotherapy
Adjuvant radiotherapy is a radiation therapy with 25 clinical trials. Currently 12 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
6
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
12
trials recruiting
25
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence
Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management
RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer
Clinical Trials (25)
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence
Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management
RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer
Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Prospective, Observational, Real-world Oral Malignant Tumors Study
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 Resection
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
Neoadjuvant Radiotherapy for Breast Cancer
Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.
Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
Radiotherapy - Adjuvant Versus Early Salvage
Accelerated Hypofractionated 1 Week Radiotherapy in Breast Cancer Patients
Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection
Adjuvant Radiotherapy's Effect on One and Two Stages Prosthetic Breast Reconstruction and on Autologous Reconstruction
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 25